CD274 and non-small cell lung carcinoma: In the first scenario analysis, although our attempts to unify the subsequent anticancer therapy in these three first-line ICI monotherapy groups did not significantly change our results, the increases in QALYs in the first-line pembrolizumab and atezolizumab groups compared with our base case results may support a case for expanding the cemiplimab plus chemotherapy indication to second-line settings for advanced NSCLC patients with PD-L1 of at least 50%.